Are you looking for lead candidate compounds for your target and do you want your drug discovery program to be more efficient, in terms of both time and cost?
Pivot Park Screening Centre (PPSC) is your optimal partner in early drug discovery.
Projects are tailored to your requirements. We provide drug discovery services in the fields of biochemical and cellular assay development, lab automation, Ultra-High-Throughput Screening (uHTS, usually in 1536-well format) and hit-to-lead biological profiling, in order to find novel leads for drug development.
All major read-out modalities are available in-house ensuring rapid generation of high-quality hits. As first CRO we integrated Mass Spectrometry (MALDI-TOF MS) into our uHTS system.
You can either bring your own compound library or use our 300K IP-free drug like compound library. Our fully automated robot system can handle over 1 mln compounds per screen. The past 10 years we have successfully completed more than 150 screening campaigns.
PPSC is located on the Life Sciences Campus Pivot Park, the former research site of MSD in the Netherlands, which focuses on pharmaceutical R&D.
About Drug Discovery Innovation Programme 2022
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2022 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2022 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.